HCV

HCV製品

All (8)
HCV阻害剤 (8)
新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例
S2728	AG-1478	AG-1478 is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).	Cell Death Dis, 2025, 16(1):479 J Stroke Cerebrovasc Dis, 2025, 34(6):108315 Biomed Pharmacother, 2024, 180:117523
S1848	Curcumin	Curcumin (Diferuloylmethane, Natural Yellow 3, Turmeric yellow) is the principal curcuminoid of the popular Indian spice turmeric, which is a member of the ginger family (Zingiberaceae). It is an inhibitor of p300 histone acetylatransferase（IC50~25 μM）and Histone deacetylase (HDAC); activates Nrf2 pathway and supresses the activation of NF-κB. Curcumin induces mitophagy, autophagy, apoptosis, and cell cycle arrest with antitumor activity. Curcumin reduces renal damage associated with rhabdomyolysis by decreasing ferroptosis-mediated cell death. Curcumin exhibits anti-infective properties against various human pathogens like the influenza virus, hepatitis C virus, HIV and so on.	J Biol Chem, 2025, 301(7):110305 Mol Pain, 2025, 21:17448069251323668 Cancer Cell Int, 2024, 24(1):303
S2310	Honokiol	Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Honokiol causes G0/G1 phase arrest, induces apoptosis, and autophagy via the ROS/ERK1/2 signaling pathway. Honokiol inhibits hepatitis C virus (HCV) infection. Phase 3.	J Adv Res, 2025, S2090-1232(25)00062-1 J Nanobiotechnology, 2025, 23(1):414 Oncol Lett, 2025, 29(4):191
S8133	Resiquimod (R-848)	Resiquimod (R-848, S28463) is an immune response modifier that acts as a potent TLR 7/TLR 8 agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α. Resiquimod reduces hepatitis C virus (HCV) infection. Phase 2.	Nature, 2025, 644(8078):1058-1068 J Virol, 2025, e0128025. Int J Nanomedicine, 2024, 19:3589-3605
S1384	Mizoribine	Mizoribine is an imidazole nucleoside and an immunosuppressant that inhibits HCV RNA replication with IC50 of ~ 100 μM for anti-HCV activity. Mizoribine is a selective inhibitor of inosine-5'-monophosphate dehydrogenase (IMPDH) and guanosine monophosphate synthetase. Mizoribine also inhibits SARS-CoV.	EMBO J, 2023, e110620. ProQuest, 2023, The Faculty of the Graduate School of Arts and Sciences Brandeis University, 2023,
S6689	Merimepodib	Merimepodib (Merimempodib, MMPD, VI-21,497, VX-497) is a potent, specific, and reversible inosine monophosphate dehydrogenase(IMPDH) inhibitor with antiviral activity against hepatitis C virus (HCV) and a variety of DNA and RNA viruses in vitro.Merimepodib is an immunosuppressive agent.	Cancer Cell, 2022, 40(9):957-972.e10 Cancer Cell, 2022, 40(9):957-972.e10
S0349	Inarigivir soproxil	Inarigivir soproxil (GS 9992, SB 9200) is an oral agonist of innate immunity that is believed to act via the activation of the RIG-I and NOD2 pathways. Inarigivir soproxil has broad-spectrum antiviral activity against RNA viruses with EC50 of 2.2 μM and 1.0 μM for HCV 1a and HCV 1b.	Transl Oncol, 2025, 51:102230
E6581^New	Mipomersen	Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B-100 (apoB-100) that causes selective degradation of apoB-100 mRNA, thereby inhibiting protein translation. This leads to reductions in low-density lipoprotein cholesterol (LDL-C) and other apoB-containing lipoprotein levels. Mipomersen is used as an adjunct treatment for homozygous familial hypercholesterolemia (FH).
S2728	AG-1478	AG-1478 is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).	Cell Death Dis, 2025, 16(1):479 J Stroke Cerebrovasc Dis, 2025, 34(6):108315 Biomed Pharmacother, 2024, 180:117523
S1848	Curcumin	Curcumin (Diferuloylmethane, Natural Yellow 3, Turmeric yellow) is the principal curcuminoid of the popular Indian spice turmeric, which is a member of the ginger family (Zingiberaceae). It is an inhibitor of p300 histone acetylatransferase（IC50~25 μM）and Histone deacetylase (HDAC); activates Nrf2 pathway and supresses the activation of NF-κB. Curcumin induces mitophagy, autophagy, apoptosis, and cell cycle arrest with antitumor activity. Curcumin reduces renal damage associated with rhabdomyolysis by decreasing ferroptosis-mediated cell death. Curcumin exhibits anti-infective properties against various human pathogens like the influenza virus, hepatitis C virus, HIV and so on.	J Biol Chem, 2025, 301(7):110305 Mol Pain, 2025, 21:17448069251323668 Cancer Cell Int, 2024, 24(1):303
S2310	Honokiol	Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Honokiol causes G0/G1 phase arrest, induces apoptosis, and autophagy via the ROS/ERK1/2 signaling pathway. Honokiol inhibits hepatitis C virus (HCV) infection. Phase 3.	J Adv Res, 2025, S2090-1232(25)00062-1 J Nanobiotechnology, 2025, 23(1):414 Oncol Lett, 2025, 29(4):191
S8133	Resiquimod (R-848)	Resiquimod (R-848, S28463) is an immune response modifier that acts as a potent TLR 7/TLR 8 agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α. Resiquimod reduces hepatitis C virus (HCV) infection. Phase 2.	Nature, 2025, 644(8078):1058-1068 J Virol, 2025, e0128025. Int J Nanomedicine, 2024, 19:3589-3605
S1384	Mizoribine	Mizoribine is an imidazole nucleoside and an immunosuppressant that inhibits HCV RNA replication with IC50 of ~ 100 μM for anti-HCV activity. Mizoribine is a selective inhibitor of inosine-5'-monophosphate dehydrogenase (IMPDH) and guanosine monophosphate synthetase. Mizoribine also inhibits SARS-CoV.	EMBO J, 2023, e110620. ProQuest, 2023, The Faculty of the Graduate School of Arts and Sciences Brandeis University, 2023,
S6689	Merimepodib	Merimepodib (Merimempodib, MMPD, VI-21,497, VX-497) is a potent, specific, and reversible inosine monophosphate dehydrogenase(IMPDH) inhibitor with antiviral activity against hepatitis C virus (HCV) and a variety of DNA and RNA viruses in vitro.Merimepodib is an immunosuppressive agent.	Cancer Cell, 2022, 40(9):957-972.e10 Cancer Cell, 2022, 40(9):957-972.e10
S0349	Inarigivir soproxil	Inarigivir soproxil (GS 9992, SB 9200) is an oral agonist of innate immunity that is believed to act via the activation of the RIG-I and NOD2 pathways. Inarigivir soproxil has broad-spectrum antiviral activity against RNA viruses with EC50 of 2.2 μM and 1.0 μM for HCV 1a and HCV 1b.	Transl Oncol, 2025, 51:102230
E6581^New	Mipomersen	Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B-100 (apoB-100) that causes selective degradation of apoB-100 mRNA, thereby inhibiting protein translation. This leads to reductions in low-density lipoprotein cholesterol (LDL-C) and other apoB-containing lipoprotein levels. Mipomersen is used as an adjunct treatment for homozygous familial hypercholesterolemia (FH).
E6581^New	Mipomersen	Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B-100 (apoB-100) that causes selective degradation of apoB-100 mRNA, thereby inhibiting protein translation. This leads to reductions in low-density lipoprotein cholesterol (LDL-C) and other apoB-containing lipoprotein levels. Mipomersen is used as an adjunct treatment for homozygous familial hypercholesterolemia (FH).